DekaBank Deutsche Girozentrale Has $12.39 Million Holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

DekaBank Deutsche Girozentrale grew its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 235.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 89,289 shares of the specialty pharmaceutical company’s stock after acquiring an additional 62,682 shares during the period. DekaBank Deutsche Girozentrale owned 0.16% of Jazz Pharmaceuticals worth $12,392,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Carroll Financial Associates Inc. raised its position in shares of Jazz Pharmaceuticals by 166.7% in the first quarter. Carroll Financial Associates Inc. now owns 200 shares of the specialty pharmaceutical company’s stock valued at $28,000 after buying an additional 125 shares in the last quarter. Machina Capital S.A.S. acquired a new stake in shares of Jazz Pharmaceuticals in the second quarter valued at approximately $29,000. Signaturefd LLC raised its position in shares of Jazz Pharmaceuticals by 56.3% in the second quarter. Signaturefd LLC now owns 200 shares of the specialty pharmaceutical company’s stock valued at $29,000 after buying an additional 72 shares in the last quarter. Osborn Williams & Donohoe LLC acquired a new stake in shares of Jazz Pharmaceuticals in the first quarter valued at approximately $33,000. Finally, Cullen Frost Bankers Inc. acquired a new stake in shares of Jazz Pharmaceuticals in the first quarter valued at approximately $93,000. Hedge funds and other institutional investors own 89.59% of the company’s stock.

Shares of NASDAQ:JAZZ opened at $134.83 on Friday. The company’s 50 day simple moving average is $138.13 and its 200 day simple moving average is $134.53. The stock has a market capitalization of $7.63 billion, a price-to-earnings ratio of 11.02, a price-to-earnings-growth ratio of 1.10 and a beta of 1.14. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.71 and a quick ratio of 3.52. Jazz Pharmaceuticals PLC has a 1 year low of $113.52 and a 1 year high of $176.73.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.16 by $0.49. The business had revenue of $534.13 million for the quarter, compared to analysts’ expectations of $507.23 million. Jazz Pharmaceuticals had a net margin of 32.99% and a return on equity of 27.72%. The firm’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period last year, the firm posted $3.49 earnings per share. As a group, analysts anticipate that Jazz Pharmaceuticals PLC will post 13.44 EPS for the current fiscal year.

In other Jazz Pharmaceuticals news, Director Catherine A. Sohn sold 726 shares of the business’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $135.65, for a total transaction of $98,481.90. Following the sale, the director now owns 9,574 shares of the company’s stock, valued at $1,298,713.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Paul Treacy sold 4,371 shares of the business’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $137.40, for a total transaction of $600,575.40. The disclosure for this sale can be found here. Company insiders own 4.30% of the company’s stock.

A number of equities research analysts have recently weighed in on the stock. Wells Fargo & Co reiterated a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Wednesday. Barclays lifted their price target on shares of Jazz Pharmaceuticals from $164.00 to $180.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. TheStreet upgraded shares of Jazz Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Wednesday, July 24th. BidaskClub upgraded shares of Jazz Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 18th. Finally, Evercore ISI reiterated a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Monday, August 12th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have given a buy rating to the stock. Jazz Pharmaceuticals presently has an average rating of “Buy” and an average target price of $176.53.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Featured Story: How interest rates affect municipal bond prices

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.